The Triad Story

Triad Life Sciences, Inc. is an emerging regenerative medicine company with a groundbreaking FDA-cleared technology platform engineered to address unmet clinical needs in complex surgical wounds, chronic stalled wounds, and burns. Triad’s proprietary, patent-pending technology provides innovative treatment solutions derived from our naturally occurring extracellular matrix (ECM) material and its related bioactive properties.

Triad was founded to disrupt the extracellular matrix (ECM) market with a platform technology that introduces the first-ever placental-derived medical device to address the inherent challenges and related restrictions of human cells, tissues, and cellular and tissue-based products (HCT/Ps).

Triad’s leadership team has well over 100 years of collective medical device experience at multiple biologics companies and over 30 years of combined experience specific to placental ECM technologies.

This combined experience allowed Triad to identify the following three key challenges with placental allografts manufactured from HCT/Ps: graft variability, minimal manipulation requirements, and the economics of care. InnovaMatrix Platform offers a unique, unparalleled solution to these challenges while also providing the reliability, reproducibility, and safety profile of a medical device.

HCT/P Problem: Graft Variability

Variability exists from graft to graft due to extensive donor variance and the lack of medical device quality systems and design controls.

Triad’s Solution: Consistency and Reliability

Triad’s new platform technology utilizes a monitored source material that is controlled for diet, age, activity levels, and health. This highly controlled source does not have the same genetic, health, and lifestyle issues that impact human donors.

HCT/P Problem: Minimal Manipulation Requirements.

Minimal manipulation requirements set by the FDA prevent HCT/P processors from altering the relevant biological characteristics of the HCT/Ps, including complete decellularization of the tissue. Cellular debris remaining in HCT/P allografts has been linked to inflammatory M1 macrophage responses by the host.

Triad’s Solution: Complete Decellularization with Protein Preservation.

As a medical device, InnovaMatrix™ Platform is not restricted by minimal manipulation requirements. InnovaMatrix™ Platform is processed with the proprietary TriCleanse™ Process, which deactivates viruses, decellularizes, and disinfects the tissue. The TriCleanse™ Process balances thorough decellularization with proper preservation of the ECM’s structural proteins to create a clean and efficient matrix for wound management.

HCT/P Problem: Economics of Care.

Both the natural size limitations and processing costs associated with human-donated tissues lead to increased pricing and reduced graft availability, which combine to limit patient access to high-performing placental ECMs, especially for complex surgical wounds, chronic stalled wounds, and burns.

Triad’s Solution: Cost Effective.

Triad passes on our recognized cost efficiencies due to our highly scalable manufacturing operation and best-in-class source material to address the economics of care for providers, payers, physicians, and patients. Triad provides ECM technologies of the highest quality at accessible prices.